Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
Tirzepatide , a dual GIP/GLP-1 receptor agonist, has been approved in the UK for type 2 diabetes (as Mounjaro) but at the time of writing is not licensed by the MHRA specifically for weight management
Early animal studies suggest this combination may lead to faster recovery times and improved structural integrity of repaired tissues
Most people can get right back to their day after the treatment is over, without any side effects or post-treatment problems
Sold for laboratory research only
Or three 10mg vials (weeks 1-8) plus three 30mg vials (weeks 9-16)
US$ 27.77
US$ 25.23
US$ 29.96
US$ 22.49
